Clinical Trials Logo

Filter by:
  • Available  
  • Page [1]
NCT ID: NCT04929158 Available - Clinical trials for ST Elevation Myocardial Infarction

Comparison of Clinical Outcomes of IVUS -Guided and Angiography-guided PCI in Patients With Acute STEMI

Start date: n/a
Phase:
Study type: Expanded Access

To compare the long-term clinical outcomes of IVUS-guided vs angiography-guided PCI in patients with acute STEMI

NCT ID: NCT04008524 Available - Clinical trials for Relapsed and Refractory Hematological Malignancies

A Clinical Study of CAR-T Cells in the Treatment of Relapsed and Refractory Hematological Malignancies

Start date: n/a
Phase:
Study type: Expanded Access

This project is intended to provide CAR-T cell therapy products for patients with severely life-threatening relapsed and refractory hematological malignancies. These patients have been previously treated sufficiently, currently have no other treatment methods available, and do not meet the inclusion criteria of other clinical trial projects in the process of subject recruitment or meet their exclusion criteria. This project is designed to meet the urgent clinical needs of individual patients.

NCT ID: NCT01995305 Available - Fanconi Anemia Clinical Trials

Use Massive Parallel Sequencing and Exome Capture Technology to Sequence the Exome of Fanconi Anemia Children and Their Patents

Start date: n/a
Phase: N/A
Study type: Expanded Access

Fanconi anemia is a rare autosomal or sex linked recessive genetic disease. The disease is characterized by bone marrow hematopoiesis failure, multiple congenital abnormalities, and susceptibility to neoplastic diseases. The cells of FA patients are extremely sensitive to MMC and DEB. The symptoms and ages of FA patients are different, so by comparing the exome of FA patients and their parents, the mutations that were accumulated in FA patients could be found, and these genes might be sensitive to repairment and be important for hematopoiesis maintainance.

NCT ID: NCT01317953 Available - Clinical trials for Small Cell Lung Carcinoma

Oral Green Tea Extract for Small Cell Lung Cancer

Start date: n/a
Phase:
Study type: Expanded Access

The purpose of this study is to determine whether green tea extract is safe for extensive-stage small lung cancer who achieved objective tumor response after first-line therapy.

NCT ID: NCT01250808 Available - Multiple Myeloma Clinical Trials

Technology Platform and System Construction of Clinical Evaluation Studies on New Drugs of Hematological Malignancy

Start date: n/a
Phase: N/A
Study type: Expanded Access

Multiple Myeloma (MM) is the second diagnosed malignancy of hematological malignancies. The previous study pointed out that the dosage and course of Bortezomib including the dose of concomitant drugs used to treatment MM patients did not get the preferred treatment program, so we are going to determine the optimal doses and course of Bortezomib through the prospective, multicenter clinical trial and evaluate the efficiency and safety of different program.